The American Heart Association (AHA) has released new clinical practice guidelines for the management of Cardiovascular-Kidney-Metabolic (CKM) syndrome, a framework designed to treat heart disease, kidney disease, and diabetes as an interconnected system rather than isolated conditions. Published in the journal Circulation on June 9, 2024, the guidelines shift medical care toward a holistic model that addresses the shared biological and social drivers of these chronic illnesses, which collectively affect nearly 90 percent of U.S. adults.
What is CKM Syndrome?
Cardiovascular-Kidney-Metabolic syndrome is a clinical framework that identifies the shared pathways between obesity, diabetes, chronic kidney disease, and cardiovascular disease. According to the AHA, these conditions are not independent; rather, dysfunction in one organ system—such as the heart or kidneys—frequently accelerates damage in others.
The framework, originally introduced in a 2023 AHA scientific statement, classifies the syndrome into four distinct stages:
- Stage 1: Presence of excess visceral adipose tissue (fat surrounding internal organs) and metabolic risk factors like insulin resistance.
- Stage 2: The development of clinical conditions including hypertension, type 2 diabetes, or chronic kidney disease.
- Stage 3: Subclinical cardiovascular disease or early signs of heart failure.
- Stage 4: Symptomatic cardiovascular disease, including heart failure, stroke, or end-stage kidney disease.
Why Integrated Care Matters
Historically, medical specialties have operated in silos, with cardiologists, nephrologists, and endocrinologists managing their respective organs independently. The new guideline, led by Dr. Chiadi Ndumele of Johns Hopkins Medicine, argues that this approach is no longer sufficient.
By recognizing the disease as a continuum, clinicians can leverage therapies that provide multi-organ benefits. For example, SGLT2 inhibitors and GLP-1 receptor agonists are highlighted in the guidelines for their ability to simultaneously improve glycemic control, reduce cardiovascular risk, and slow the progression of chronic kidney disease. This proactive management, according to the guideline committee, allows for earlier intervention before a patient reaches the advanced, symptomatic stages of the syndrome.
The Role of Social Determinants in Health
The guideline identifies social determinants of health—such as food insecurity, housing instability, and limited access to care—as primary drivers of CKM syndrome progression. Because these factors directly influence a patient’s ability to manage metabolic health, the AHA recommends that clinical teams incorporate social workers and community health workers into the standard care model.
"We cannot address the biological progression of these diseases without also addressing the environment in which the patient lives," says Dr. Susanne Nicholas, a nephrologist at UCLA. The guidelines provide clinicians with specific toolkits to screen for social risks and discuss weight management in a non-stigmatizing, evidence-based manner.
Improving Kidney Health Detection
A major focus of the new guidance is the under-diagnosis of chronic kidney disease. Many patients remain unaware of their condition until symptoms appear, which is often late in the disease process. The AHA recommends that primary care providers expand screening beyond the standard estimated glomerular filtration rate (eGFR) to include the urine albumin-to-creatinine ratio (UACR). This test can identify kidney damage in its earliest stages, allowing for earlier therapeutic intervention.
Key Takeaways for Patients
- Unified Screening: Patients should expect a more integrated approach where primary care providers screen for heart, kidney, and metabolic risks simultaneously.
- Early Detection: Routine monitoring for kidney health may now include urine albumin tests, which are more sensitive to early damage than blood filtration tests alone.
- Comprehensive Treatment: Clinicians are encouraged to prioritize medications that provide "cross-system" protection, such as those that treat both diabetes and heart failure.
- Holistic Support: If you are managing multiple metabolic conditions, ask your provider about connecting with a care team that includes social support resources to address barriers like medication costs or healthy food access.